Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5105338 | 0.89 | CYP1A2 (0.40) | PPARGPTGDR2CYP1A2AKR1B1CYSLTR1 | |
| SCHEMBL5114575 | 0.84 | CYSLTR1 (0.45) | PPARGPTGDR2CYP1A2AKR1B1CYSLTR1 | |
| SCHEMBL5109080 | 0.82 | CYSLTR2 (0.46) | PPARGPTGDR2CYP1A2CYSLTR1CYSLTR2 | |
| SCHEMBL5112024 | 0.81 | PPARG (0.42) | PPARG | |
| SCHEMBL5120100 | 0.81 | PPARG (0.50) | PPARGCYP1A2 | |
| SCHEMBL5114784 | 0.78 | PPARG (0.47) | PPARG | |
| SCHEMBL5114268 | 0.77 | PPARG (0.69) | PPARGPTGDR2CYP1A2AKR1B1CYSLTR1 | |
| SCHEMBL5118890 | 0.77 | PPARG (0.57) | PPARG | |
| SCHEMBL5113441 | 0.76 | PPARG (0.54) | PPARG | |
| SCHEMBL5113246 | 0.75 | SMN1; SMN2 (0.44) | PTGDR2CYP1A2AKR1B1CYSLTR1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885PTGDR2 2631/4885CYP1A2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.